Vorapaxar

Reviewed on 8/27/2021

Brand Name and Other Names: Zontivity

Generic Name: Vorapaxar

Drug Class: Antiplatelet Agents, Cardiovascular; Thrombin Inhibitors; Protease Activated Receptor-1 (PAR-1) Inhibitors

What Is Vorapaxar Used For and How Does it Work?

Vorapaxar is used to reduce thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction or MI), or with peripheral arterial disease.

Vorapaxar is available under the following different brand names: Zontivity.

What Are the Dosages of Vorapaxar?

Dosages of Vorapaxar:

Dosage Forms and Strengths

Tablet

  • 2.08mg

Dosage Considerations – Should be Given as Follows:

Thromboembolism

  • Indicated to reduce thrombotic cardiovascular events in patients with a history of MI or with peripheral arterial disease
  • 2.08 mg orally once daily in combination with either aspirin and/or clopidogrel (according to their indications or standard of care); there is limited clinical experience with other antiplatelet drugs and none with vorapaxar as the only antiplatelet agent

Dosage Modifications

  • Renal impairment: No dose adjustment is required
  • Mild-to-moderate hepatic impairment: No dose adjustment required
  • Severe hepatic impairment: Not recommended; based on the increased inherent risk of bleeding in patients with severe hepatic impairment
Dosing Considerations

Administration

  • May take with or without food

QUESTION

In the U.S., 1 in every 4 deaths is caused by heart disease. See Answer

What Are Side Effects Associated with Using Vorapaxar?

Common side effects of Vorapaxar include:

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

What Other Drugs Interact with Vorapaxar?

  • Severe interactions of vorapaxar include:
  • Vorapaxar has serious interactions with at least 46 different drugs.
  • Vorapaxar has moderate interactions with at least 73 different drugs.
  • Vorapaxar has no listed mild interactions with other drugs.

What Are Warnings and Precautions for Vorapaxar?

Warnings

  • This medication contains vorapaxar. Do not take Zontivity if you are allergic to vorapaxar or any ingredients contained in this drug.

Black Box Warnings

Contraindications

  • History of stroke, TIA, or ICH because of an increased risk of ICH in this population
  • Active pathologic bleeding

Effects of Drug Abuse

  • No information is available.

Short-Term Effects

  • See "What Are Side Effects Associated with Using Vorapaxar?"

Long-Term Effects

  • See "What Are Side Effects Associated with Using Vorapaxar?"

Cautions

  • Discontinue in patients who experience a stroke, TIA, or ICH
  • Antiplatelet agents, including vorapaxar, increase the risk of bleeding, including ICH and fatal bleeding (see Black Box Warnings)
  • Strong CYP3A inhibitors increase and inducers decrease vorapaxar exposure; avoid coadministration

Pregnancy and Lactation

  • Based on the potential for serious adverse reactions (such as maternal bleeding/hemorrhage) and long half-life which makes it effectively irreversible, discontinue vorapaxar therapy when pregnancy is detected and initiate alternative therapy with a shorter duration of action. Available data from postmarketing experience with use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
  • There are no data on the presence of vorapaxar or metabolites in human milk, its effects on the breastfed infant, or milk production. When vorapaxar was administered to lactating rats, the drug was actively secreted in the milk of rats. When a drug is present in animal milk, it is likely the drug will be present in human milk. Because of the potential for serious adverse reactions in breastfed infants, such as bleeding, breastfeeding is not recommended during treatment with vorapaxar.
References
https://reference.medscape.com/drug/zontivity-vorapaxar-999911

Health Solutions From Our Sponsors